1351 related articles for article (PubMed ID: 12528874)
1. Review of 1027 patients with newly diagnosed multiple myeloma.
Kyle RA; Gertz MA; Witzig TE; Lust JA; Lacy MQ; Dispenzieri A; Fonseca R; Rajkumar SV; Offord JR; Larson DR; Plevak ME; Therneau TM; Greipp PR
Mayo Clin Proc; 2003 Jan; 78(1):21-33. PubMed ID: 12528874
[TBL] [Abstract][Full Text] [Related]
2. Serum albumin level is a significant prognostic factor reflecting disease severity in symptomatic multiple myeloma.
Kim JE; Yoo C; Lee DH; Kim SW; Lee JS; Suh C
Ann Hematol; 2010 Apr; 89(4):391-7. PubMed ID: 19844712
[TBL] [Abstract][Full Text] [Related]
3. Simple prognostic model for patients with multiple myeloma: a single-center study in Japan.
Kaneko M; Kanda Y; Oshima K; Nannya Y; Suguro M; Yamamoto R; Chizuka A; Hamaki T; Matsuyama T; Takezako N; Miwa A; Togawa A
Ann Hematol; 2002 Jan; 81(1):33-6. PubMed ID: 11807633
[TBL] [Abstract][Full Text] [Related]
4. Connect MM Registry: The Importance of Establishing Baseline Disease Characteristics.
Rifkin RM; Abonour R; Terebelo H; Shah JJ; Gasparetto C; Hardin J; Srinivasan S; Ricafort R; Nagarwala Y; Durie BG
Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):368-76. PubMed ID: 25617035
[TBL] [Abstract][Full Text] [Related]
5. International staging system for multiple myeloma.
Greipp PR; San Miguel J; Durie BG; Crowley JJ; Barlogie B; Bladé J; Boccadoro M; Child JA; Avet-Loiseau H; Kyle RA; Lahuerta JJ; Ludwig H; Morgan G; Powles R; Shimizu K; Shustik C; Sonneveld P; Tosi P; Turesson I; Westin J
J Clin Oncol; 2005 May; 23(15):3412-20. PubMed ID: 15809451
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic criteria of multiple myeloma.
Kyle RA
Hematol Oncol Clin North Am; 1992 Apr; 6(2):347-58. PubMed ID: 1582977
[TBL] [Abstract][Full Text] [Related]
7. Multiple myeloma: review of 869 cases.
Kyle RA
Mayo Clin Proc; 1975 Jan; 50(1):29-40. PubMed ID: 1110582
[TBL] [Abstract][Full Text] [Related]
8. Prognostic factors and staging systems of multiple myeloma:
Tao ZF; Fu WJ; Yuan ZG; Wang DX; Chen YB; Hou J
Chin Med J (Engl); 2007 Oct; 120(19):1655-8. PubMed ID: 17935664
[TBL] [Abstract][Full Text] [Related]
9. [Prognostic analysis and assessment on the clinical staging systems of multiple myeloma--a report of 206 cases].
Tao ZF; Fu WJ; Chen YB; Yuan ZG; Wang DX; Hou J
Ai Zheng; 2006 Apr; 25(4):461-4. PubMed ID: 16613681
[TBL] [Abstract][Full Text] [Related]
10. Multiple-myeloma: review of 231 cases.
Advani SH; Soman CS; Talwalkar GV; Lyer YS; Bhatia HM
Indian J Cancer; 1978 Jun; 15(2):55-61. PubMed ID: 374240
[No Abstract] [Full Text] [Related]
11. Time to first disease progression, but not beta2-microglobulin, predicts outcome in myeloma patients who receive thalidomide as salvage therapy.
Palumbo A; Bringhen S; Falco P; Cavallo F; Ambrosini MT; Avonto I; Gay F; Caravita T; Bruno B; Boccadoro M
Cancer; 2007 Aug; 110(4):824-9. PubMed ID: 17594696
[TBL] [Abstract][Full Text] [Related]
12. Prognostic factors in multiple myeloma.
Kyle RA
Stem Cells; 1995 Aug; 13 Suppl 2():56-63. PubMed ID: 8520513
[TBL] [Abstract][Full Text] [Related]
13. Staging multiple myeloma patients with active disease using serum levels of beta2m-free HLA class I heavy chain together with IgM or platelet count.
Perosa F; Minoia C; Favoino E; Prete M; Dammacco F
Blood Cells Mol Dis; 2009; 42(1):71-6. PubMed ID: 18996035
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of the serum phosphorus level and its relationship with other prognostic factors in multiple myeloma.
Umeda M; Okuda S; Izumi H; Nagase D; Fujimoto Y; Sugasawa Y; Arai C; Natori K; Katoh M; Kuraishi Y
Ann Hematol; 2006 Jul; 85(7):469-73. PubMed ID: 16528526
[TBL] [Abstract][Full Text] [Related]
15. [The clinical features, chemotherapy responses and survival of 223 patients with newly diagnosed multiple myeloma].
Li J; Zhao Y; Luo SK; Huang BH; Zhang GC; Peng AH; Zheng D; Su C; Xu DR; Tong XZ; Gu JL; Ding Y
Zhonghua Yi Xue Za Zhi; 2008 Aug; 88(30):2140-3. PubMed ID: 19080477
[TBL] [Abstract][Full Text] [Related]
16. Factors affecting outcome of patients with multiple myeloma.
Basit A; Siddiqui N; Hameed A; Muzaffar N; Athar S
J Ayub Med Coll Abbottabad; 2014; 26(3):376-9. PubMed ID: 25671952
[TBL] [Abstract][Full Text] [Related]
17. Total soluble HLA class I and soluble HLA-G in multiple myeloma and monoclonal gammopathy of undetermined significance.
Leleu X; Le Friec G; Facon T; Amiot L; Fauchet R; Hennache B; Coiteux V; Yakoub-Agha I; Dubucquoi S; Avet-Loiseau H; Mathiot C; Bataille R; Mary JY;
Clin Cancer Res; 2005 Oct; 11(20):7297-303. PubMed ID: 16243800
[TBL] [Abstract][Full Text] [Related]
18. [Prognostic factors and markers of activity in multiple myeloma (results of the Cooperative Group for Diagnosis and Treatment of Multiple Myeloma)].
Spicka I; Cieslar P; Procházka B; Jirsa M; Chrz M; Gregora E; Klener P
Cas Lek Cesk; 2000 Apr; 139(7):208-12. PubMed ID: 10916207
[TBL] [Abstract][Full Text] [Related]
19. [Biochemical and immunological findings of multiple myeloma].
Asaoku H
Nihon Rinsho; 2007 Dec; 65(12):2256-60. PubMed ID: 18069270
[TBL] [Abstract][Full Text] [Related]
20. Should bone marrow examination be routinely performed for the diagnosis of monoclonal gammopathy of undetermined significance?
Elis A; Radnay J; Shapiro H; Itzhaky D; Manor Y; Lishner M
Isr Med Assoc J; 2006 Dec; 8(12):840-2. PubMed ID: 17214099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
